4.6 Article

DOSE-DEPENDENT EFFECT OF ANTI-CTLA-4 ON SURVIVAL IN SEPSIS

Related references

Note: Only part of the references are listed.
Review Immunology

Targeting inhibitory pathways in cancer immunotherapy

Marcio O. Lasaro et al.

CURRENT OPINION IN IMMUNOLOGY (2010)

Editorial Material Medicine, General & Internal

Immunotherapy for Sepsis - A New Approach against an Ancient Foe

Richard S. Hotchkiss et al.

NEW ENGLAND JOURNAL OF MEDICINE (2010)

Article Medicine, General & Internal

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

F. Stephen Hodi et al.

NEW ENGLAND JOURNAL OF MEDICINE (2010)

Review Immunology

PD-1 signaling in primary T cells

James L. Riley

IMMUNOLOGICAL REVIEWS (2009)

Article Multidisciplinary Sciences

PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis

Xin Huang et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)

Article Critical Care Medicine

TARGETED DELIVERY OF siRNA TO CELL DEATH PROTEINS IN SEPSIS

Pavan Brahmamdam et al.

SHOCK (2009)

Article Immunology

Downregulation of CD40 Ligand Response in Monocytes from Sepsis Patients

Anna Sinistro et al.

CLINICAL AND VACCINE IMMUNOLOGY (2008)

Article Immunology

Twelve immunotherapy drugs that could cure cancers

Martin A. ‘Mac’ Cheever

IMMUNOLOGICAL REVIEWS (2008)

Article Medicine, Research & Experimental

CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells

Sergio A. Quezada et al.

JOURNAL OF CLINICAL INVESTIGATION (2006)

Article Immunology

CTLA-4 regulates the murine immune response to Trypanosoma cruzi infection

SEB Graefe et al.

PARASITE IMMUNOLOGY (2004)

Review Medicine, General & Internal

Medical progress: The pathophysiology and treatment of sepsis.

RS Hotchkiss et al.

NEW ENGLAND JOURNAL OF MEDICINE (2003)